The incretin system From genetic determinants to impact on early development of...
The incretin system From genetic determinants to impact on early development of type 2 diabetes in the population
The incretin hormones (GLP-1 and GIP) are secreted from the gut in response to food intake and their primary role is to amplify nutrient-induced insulin release. Most of this effect is lost in obesity and type 2 diabetes. Glucagon...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
INSIGHT
An Integrated Network of Glucose Sensing Cells in Glucose H...
2M€
Cerrado
Multi-Islet
Development of Multiscale Analysis of Pancreatic Beta Cell F...
200K€
Cerrado
BFU2012-33594
CONTROL EPIGENETICO DE LA ADAPTACION DE LA CELULA BETA A LA...
47K€
Cerrado
OptoBETA
Multicellular regulation of insulin secretion from pancreati...
2M€
Cerrado
BRIDIT
Beta cell Receptors in Diabetes Therapy
231K€
Cerrado
HuPIPA
A Human Pancreatic Islet Perturbation Atlas (HuPIPA) to deci...
165K€
Cerrado
Información proyecto INSGEN
Líder del proyecto
KOBENHAVNS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
231K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The incretin hormones (GLP-1 and GIP) are secreted from the gut in response to food intake and their primary role is to amplify nutrient-induced insulin release. Most of this effect is lost in obesity and type 2 diabetes. Glucagon acts as a counter-regulatory hormone to insulin and may therefore also be essential in type 2 diabetes pathophysiology. My objective is to carry out a unique combination of state-of-the-art phenotyping and genotyping in a large, well-characterized cohort of people at key stages of increased diabetes risk. I will genotype a large panel of more than 500,000 genetic markers in 2,082 individuals with varying levels of glucose tolerance, either normal glucose tolerance, impaired fasting glycaemia, impaired glucose tolerance or type 2 diabetes. In addition, I will measure plasma levels of GLP-1, GIP and glucagon at 0, 30 and 120 minutes during an oral glucose tolerance test in the same individuals. I will then examine the effect of these genetic markers on incretin and glucagon levels during the oral glucose challenge. The results of the association study will be followed up in an additional cohort consisting of ~8,200 individuals from Sweden and Finland. The knowledge generated about the complex interplay of mechanisms driving the earliest stages of diabetes will allow identification of new potential targets for individualized prevention and treatment of type 2 diabetes. The epidemiological scale of the study will enable a direct translation of the findings to the real-life setting of population-wide general practice-based diabetes screening and tailored prevention.